Effection Observation Of Hepatic Artery Embolism Chemotherapy Combined With Antiviral Treatment In Inpatients With Heatocellular Carcinoma

Objective:To study the TACE (transcatheter arterial chemoembolization) combined withantiviral therapy in patients with HCC (heatocellular carcinoma) in the clinicalcurative effect.Methods:Through the prospective study, we continued collecting254cases of in patientstreated with conventional (line54cases of them have been surgery) in the firstaffiliated hospital of Nanchang university in September2010to December2012,based on conventional TACE patients overall curative effect analysis, analysis ofprognostic factors, antiviral curative effect. According to whether patients withantiviral treatment was divided into randomly, antiviral treatment group (treatmentgroup) and without antiviral treatment group (control group),67cases patients oftreatment group, the control group70cases of patients, the treatment group in thehepatic artery chemotherapy embolism with conventional therapy on the basis of jointnucleotide analogs antiviral therapy and control group in line with conventionaltreatment alone. survival rate and survival curve, HBV turn rate and activation rate,AFP, ECOG,Child-Pugh, classification of two groups of patients, solid tumor curativeeffect, the time of disease progression。 Using SPSS17.0statistical software for dataanalysis; Measurement data using t test, counting data by chi-square test; As KaplanMeier survival curve, the survival function of the log-rank test. Kaplan Meier-andapplication method of single factor analysis, screening prognostic factors, andsurvival curve drawing, and multifactor analysis, using COX regression filter to hadindependent prognosis factors; P <0.05there were significant differences.Results:（1）254cases of patients with TTP was4.42+/-2.71months and the mediansurvival time was15.0months, six months: survival rate82.0%;9months survivalrate:72.0%; Survival rates:62.0%in the12months;18months survival rate:42.0%;24months survival rate:36.0%. （2）Treatment group compared with control group;1. Survival compared:18months X~2=2.127, P>2.127, no statistical significance,24months X~2=10.66P <0.05difference was statistically significant.2. HBV activation rate compared: X~2=5.391,P <0.05difference was statistically significant.3. turn rate compared:X~2=5.391P<0.05difference was statistically significant.4. AFP compared:3months after，Treatment group (treatment before530.41+/-88.40to512.37+85.47) aftertreatment t=0.502, P>0.05, the control group before treatment (459.44+/-98.18to436.92+90.29) after treatment t=0.169, P>0.05, the difference had no statisticalsignificance.6months after Treatment group (treatment before530.41+/-88.40to498.37+79.65) after treatment t=0.674, P>0.05, the control group before treatment(459.44+/-98.18to412.35+96.78) after treatment t=0.895, P>0.05, the difference hadno statistical significance.5. Per patient, on average, physical status score changedcomparison:0months,3months,6months after the treatment group was0.805,0.955,1.211, and the control group,1.085,1.220,0.800, P>0.05, the difference hadno statistical significance.6. Child-Pugh, classification comparison: the treatmentgroup (before7.24+/-1.236months treatment of7.24+/-1.2112months to7.10+1.09) in control group (7.27+/-1.326months treatment of7.54+/-1.07treatment7.70+1.11) for12months,3months after t=0.990, there was no statistically significantdifference (P>0.05), and6months after t=2.214, P<0.05,12months after t=2.247,P<0.05, differences had statistical significance.7. Solid tumor curative effect rateand Stable rate compared: after6months of treatment group compared with controlgroup, effect rate1)=0.198, P>0.05, Stable rate2) the chi square=0.327, P>0.05),there was no statistically significant difference; atfter12months curative effect1) the chi square=0.826, P>0.826); Stable rate2) the chi square=0.179, P>0.05)there was no statistically significant difference;.（3） Eight prognosis factor of single factor in addition to gender, age (P>0.05),ascites and portal vein tumor emboli, cirrhosis of the liver and extrahepatic metastasis,surgical procedure, antiviral treatment5variables, difference had statisticalsignificance (P<0.05); Prognostic factors in factor analysis, portal vein tumor emboli,cirrhosis of the liver, relative risk Exp (B) were0.598,0.476<1, for the risk factors,the antiviral treatment and surgery and relative risk Exp (QB) were1.640,1.640>1, in order to protect factors.Conclusion:（1）TACE with nucleoside analogues (acid) antiviral treatment could inhibit thehepatitis B-virus replication, stability in patients with liver function, improved thequality of survival, prolong the survival period, has good clinical effect。（2）8single factor, the sex, age six other outside factors were independent riskfactors affecting prognosis of primary liver cancer, including portal vein tumoremboli, cirrhosis of the liver2prognostic factors for risk factors, surgery,antiretroviral treatment was to protect factors。...